share_log

11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

11-K：員工持股年度報告
美股sec公告 ·  06/21 22:40
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a global healthcare company, has filed its annual Form 11-K report with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2023. The report includes audited financial statements for the Novo Nordisk Inc. 401(k) Savings Plan, which is a defined contribution plan for U.S. employees. The independent auditor, EisnerAmper LLP, has expressed an unqualified opinion that the financial statements present fairly the net assets available for benefits and the changes therein for the years ended December 31, 2023, and 2022. The Plan's net assets available for benefits increased significantly from $1,769,202,694 in 2022 to $2,303,296,181 in 2023. The Plan offers a variety of investment options, including mutual funds, common stock, and common collective trusts, with the fair value...Show More
Novo Nordisk A/S, a global healthcare company, has filed its annual Form 11-K report with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2023. The report includes audited financial statements for the Novo Nordisk Inc. 401(k) Savings Plan, which is a defined contribution plan for U.S. employees. The independent auditor, EisnerAmper LLP, has expressed an unqualified opinion that the financial statements present fairly the net assets available for benefits and the changes therein for the years ended December 31, 2023, and 2022. The Plan's net assets available for benefits increased significantly from $1,769,202,694 in 2022 to $2,303,296,181 in 2023. The Plan offers a variety of investment options, including mutual funds, common stock, and common collective trusts, with the fair value of investments in Novo Nordisk A/S common stock reported at $540,264,197 as of December 31, 2023. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA) and is designed to be in compliance with the Internal Revenue Code. The Plan's investments are subject to market risks and uncertainties, which could materially affect account balances and the values of net assets available for benefits.
全球醫療保健公司Novo Nordisk A/S向美國證券交易所提交了其截至2023年12月31日的年度11-K表格報告。該報告包括Novo Nordisk Inc.401(k)儲蓄計劃的審計財務報表，該計劃是美國員工的定義貢獻計劃。獨立核數師EisnerAmper LLP已經發表了無保留意見，認爲財務報表公平地反映了2023年和2022年的福利淨資產及其變動情況。計劃的福利淨資產從2022年的1,769,202,694美元增長到2023年的2,303,296,181美元。該計劃提供各種投資選擇，包括共同基金、普通股和普通集合信託基金，並且截至2023年12月31日，Novo Nordisk A/S普通股投資的公允價值報告爲540,264,197美元。該計劃受到《員工退休收入保障法》的規定約束，並旨在符合《內部收入法典》的合規要求。該計劃的投資可能面臨市場風險和不確定性，這可能會對帳户餘額和福利淨資產的價值產生重大影響。
全球醫療保健公司Novo Nordisk A/S向美國證券交易所提交了其截至2023年12月31日的年度11-K表格報告。該報告包括Novo Nordisk Inc.401(k)儲蓄計劃的審計財務報表，該計劃是美國員工的定義貢獻計劃。獨立核數師EisnerAmper LLP已經發表了無保留意見，認爲財務報表公平地反映了2023年和2022年的福利淨資產及其變動情況。計劃的福利淨資產從2022年的1,769,202,694美元增長到2023年的2,303,296,181美元。該計劃提供各種投資選擇，包括共同基金、普通股和普通集合信託基金，並且截至2023年12月31日，Novo Nordisk A/S普通股投資的公允價值報告爲540,264,197美元。該計劃受到《員工退休收入保障法》的規定約束，並旨在符合《內部收入法典》的合規要求。該計劃的投資可能面臨市場風險和不確定性，這可能會對帳户餘額和福利淨資產的價值產生重大影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。